Autres langues Dova Pharmaceuticals, Inc.

Actions

DOVA

US25985T1025

Recherche biotechnologique et médicale

Temps Différé Nasdaq			Varia. 5j.	Varia. 1 janv.
- ^USD	-.--%		-0,07%	+269,92%

06/08/19	Transcript : Dova Pharmaceuticals, Inc., Q2 2019 Earnings Call, Aug 06, 2019
27/06/19	Transcript : Dova Pharmaceuticals, Inc. - Special Call

Autres langues

09/12/19	Dova Pharmaceuticals Presents Additional Analyses from the Phase 3 Study - Core and Extension Phase - with Avatrombopag
09/12/19	Dova Pharmaceuticals Presents Additional Analyses from the Phase 3 Study Core and Extension Phase
09/12/19	Dova Pharmaceuticals Demonstrates Cost-Effectiveness of Doptelet (Avatrombopag) for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease
05/12/19	Sobi and Dova Pharmaceuticals to Present New Data from Studies with Avatrombopag for the Treatment of Thrombocytopenia in Adult Patients with Chronic Liver Disease as Well as Patients with Chronic Immune Thrombocytopenia
13/11/19	Dova Pharmaceuticals, Inc.(NasdaqGM:DOVA) dropped from NASDAQ Composite Index
12/11/19	Dova Pharmaceuticals, Inc. Announces Executive Changes
12/11/19	Dova Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019
12/11/19	Swedish Orphan Biovitrum AB (OM:SOBI) completed the acquisition of Dova Pharmaceuticals, Inc. from Paul B. Manning, Sean Stalfort and other shareholders.
11/11/19	Dova Pharmaceuticals, Inc.(NasdaqGM:DOVA) dropped from S&P TMI Index
11/11/19	Dova Pharmaceuticals, Inc.(NasdaqGM:DOVA) dropped from S&P Global BMI Index
11/11/19	Dova Pharmaceuticals, Inc.(NasdaqGM:DOVA) dropped from NASDAQ Biotechnology Index
01/10/19	Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) on Behalf of Dova Shareholders and Encourages Dova Investors to Contact the Firm
30/09/19	Dova Pharmaceuticals to be Acquired by Swedish Orphan Biovitrum AB (Sobi)
30/09/19	Swedish Orphan Biovitrum AB (OM:SOBI) entered into a definitive agreement to acquire Dova Pharmaceuticals, Inc. from Paul B. Manning, Sean Stalfort, and other shareholders for approximately $790 million.
25/09/19	Dova Pharmaceuticals to Present at 2019 Cantor Global Healthcare Conference
03/09/19	Dova Pharmaceuticals to Present at Upcoming Investor Conferences
06/08/19	Dova Pharmaceuticals to Present at 2019 Wedbush PacGrow Healthcare Conference
06/08/19	Dova Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019
06/08/19	Dova Pharmaceuticals Reports Second Quarter 2019 Operating and Financial Results
30/07/19	Dova Pharmaceuticals to Announce Second Quarter 2019 Financial Results on August 6, 2019
19/07/19	Dova Pharmaceuticals Announces Availability of DOPTELET in the United States for Treatment of Chronic Immune Thrombocytopenia
19/07/19	Dova Pharmaceuticals Announces DOPTELET® (avatrombopag) Now Commercially Available in the United States for Treatment of Chronic Immune Thrombocytopenia (ITP)
27/06/19	Dova Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for DOPTELET for Treatment of Chronic Immune Thrombocytopenia
27/06/19	Dova Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for DOPTELET® (avatrombopag) for Treatment of Chronic Immune Thrombocytopenia (ITP)
25/06/19	Dova Pharmaceuticals Announces European Union Marketing Authorization for DOPTELET® (Avatrombopag) for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease